MYNVAX PRIVATE LIMITED

MYNVAX PRIVATE LIMITED is primarily a biopharmaceutical manufacturing company, not a trading company. Its core business model revolves around the research, development, and eventual production of its proprietary vaccine candidates.

Company Introduction:

MYNVAX PRIVATE LIMITED is an innovative biopharmaceutical company based in India, primarily focused on the research, development, and manufacturing of novel vaccine candidates. The company is dedicated to addressing global health challenges by developing safe and effective vaccines against infectious diseases.

Utilizing advanced biotechnology platforms, MYNVAX engages in discovery, preclinical development, and clinical trials for its vaccine programs. Their pipeline often includes candidates for high-impact diseases, such as their notable work on COVID-19 vaccines. The company aims to establish robust manufacturing capabilities to produce these vaccines at scale once they complete development and regulatory approvals. This integrated approach, from research and development to potential large-scale production, firmly positions MYNVAX as a manufacturing-oriented enterprise within the biopharmaceutical sector. They collaborate with scientific institutions, government bodies, and other industry partners to accelerate their development efforts and bring their innovative vaccines to market.

MYNVAX PRIVATE LIMITED manufactures and sells:

* Vaccines

* Biologicals

* Biosimilars

* Pharmaceutical formulations

* Nutraceuticals